MMS-TrialAssure hires compliance, transparency director

CANTON TWP.—MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced the hiring of Kelly Valliant as director of global transparency strategy and compliance.

Vaillant will lead transparency and compliance efforts across MMS and TrialAssure global operations. TrialAssure, a software company focused on advancing clinical trial transparency, is the technology arm of MMS.

Bringing more than 20 years of clinical development experience, Vaillant has led various functions across clinical development at Gilead Sciences, Ambit Biosciences, Novartis, Amgen, and Pharmacia. He has developed and implemented processes, technologies, and systems that enable more effective, efficient, and secure sharing of clinical trial information.

“MMS and its technology, the TrialAssure suite of applications for facilitating transparency and patient engagement, are leading the effort of enhancing transparency in the drug development space,” said Michelle Gayari, MMS executive director of global operations. “The addition of Kelly Vaillant to guide these efforts is paramount in developing and refining future innovations. His expertise is well established, and the vision and leadership that Kelly brings is critical as we strive to create a more transparent future in pharma.”

Vaillant’s responsibilities include:

  • Leading and advancing the group’s overall transparency vision, strategy, and innovation
  • Providing transparency consulting, strategic advice, and operational execution in drug, device, or diagnostic developments
  • Providing technical expertise on regulatory requirements and health authority guidance for transparency and clinical trial disclosure activities
  • Assisting clients and colleagues in navigating and training on clinical trial transparency regulations, processes, and systems
  • Bringing a “Design for Transparency” approach to ensure alignment across the organization

“I wanted to join a team at the forefront of pharmaceutical innovation, and MMS and its TrialAssure technology exceed that mark,” Vaillant said. “If I can assist in developing strategies and implementing tools related to responsible data sharing that will speed research and allow for better medical decisions, I would consider myself successful.”

TrialAssure recently announced free use of its flagship TrialAssure Registry product for academic institutions, and the company was recently named Data Solution of the Year—Healthcare in the 2020 Data Breakthrough Awards.

Learn more about TrialAssure’s transparency leadership at More about MMS at or follow MMS on LinkedIn.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.